Vanda Pharmaceuticals IncNASDAQ:VNDA
- LAST PRICE5.0950
- TODAY'S CHANGE (%)0.0050 (0.0982%)
- Bid / Lots5.0900/ 19
- Ask / Lots5.1000/ 4
- Open / Previous Close5.1500 / 5.0900
- Day Range
- 52 Week Range
- Volume312,494
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VNDA |
|---|---|---|
| 09:32 ET | 17196 | 5.13 |
| 09:33 ET | 13645 | 5.145 |
| 09:35 ET | 3881 | 5.16 |
| 09:37 ET | 5405 | 5.17 |
| 09:39 ET | 498 | 5.18 |
| 09:42 ET | 3900 | 5.165 |
| 09:44 ET | 3805 | 5.15 |
| 09:46 ET | 1997 | 5.15 |
| 09:48 ET | 2925 | 5.14 |
| 09:50 ET | 9104 | 5.1497 |
| 09:51 ET | 2000 | 5.14 |
| 09:53 ET | 11819 | 5.1315 |
| 09:55 ET | 8160 | 5.14 |
| 09:57 ET | 3699 | 5.115 |
| 10:00 ET | 4555 | 5.1105 |
| 10:02 ET | 3513 | 5.08 |
| 10:04 ET | 877 | 5.085 |
| 10:06 ET | 100 | 5.085 |
| 10:08 ET | 5270 | 5.1 |
| 10:09 ET | 1800 | 5.065 |
| 10:11 ET | 800 | 5.06 |
| 10:13 ET | 3980 | 5.04 |
| 10:15 ET | 10720 | 5.05 |
| 10:18 ET | 2463 | 5.05 |
| 10:20 ET | 3593 | 5.07 |
| 10:22 ET | 1000 | 5.08 |
| 10:26 ET | 100 | 5.075 |
| 10:27 ET | 3054 | 5.09 |
| 10:31 ET | 1000 | 5.085 |
| 10:33 ET | 1980 | 5.09 |
| 10:36 ET | 4695 | 5.0948 |
| 10:38 ET | 210 | 5.09 |
| 10:40 ET | 1827 | 5.1 |
| 10:44 ET | 100 | 5.095 |
| 10:47 ET | 6165 | 5.105 |
| 10:49 ET | 700 | 5.105 |
| 10:51 ET | 200 | 5.105 |
| 10:54 ET | 1135 | 5.095 |
| 10:56 ET | 2300 | 5.0927 |
| 10:58 ET | 500 | 5.095 |
| 11:00 ET | 1000 | 5.0908 |
| 11:02 ET | 2050 | 5.105 |
| 11:05 ET | 800 | 5.1 |
| 11:09 ET | 500 | 5.095 |
| 11:12 ET | 100 | 5.095 |
| 11:14 ET | 100 | 5.095 |
| 11:16 ET | 758 | 5.1 |
| 11:21 ET | 2300 | 5.105 |
| 11:23 ET | 2952 | 5.085 |
| 11:25 ET | 200 | 5.0898 |
| 11:27 ET | 100 | 5.085 |
| 11:32 ET | 400 | 5.08 |
| 11:34 ET | 500 | 5.095 |
| 11:36 ET | 200 | 5.1 |
| 11:38 ET | 3700 | 5.08 |
| 11:39 ET | 705 | 5.09 |
| 11:41 ET | 100 | 5.095 |
| 11:43 ET | 100 | 5.095 |
| 11:45 ET | 1200 | 5.09 |
| 11:50 ET | 3300 | 5.085 |
| 11:52 ET | 200 | 5.085 |
| 11:57 ET | 200 | 5.09 |
| 12:01 ET | 100 | 5.085 |
| 12:06 ET | 200 | 5.09 |
| 12:12 ET | 306 | 5.085 |
| 12:14 ET | 624 | 5.08 |
| 12:17 ET | 3000 | 5.0761 |
| 12:19 ET | 100 | 5.075 |
| 12:21 ET | 200 | 5.075 |
| 12:24 ET | 1699 | 5.07 |
| 12:26 ET | 1554 | 5.065 |
| 12:28 ET | 908 | 5.075 |
| 12:32 ET | 1539 | 5.07 |
| 12:33 ET | 701 | 5.07 |
| 12:35 ET | 350 | 5.07 |
| 12:37 ET | 302 | 5.075 |
| 12:39 ET | 100 | 5.075 |
| 12:42 ET | 701 | 5.075 |
| 12:44 ET | 4158 | 5.07 |
| 12:46 ET | 100 | 5.065 |
| 12:48 ET | 100 | 5.065 |
| 12:50 ET | 387 | 5.06 |
| 12:51 ET | 250 | 5.055 |
| 12:53 ET | 830 | 5.0601 |
| 12:55 ET | 100 | 5.065 |
| 01:04 ET | 100 | 5.07 |
| 01:06 ET | 4813 | 5.075 |
| 01:08 ET | 900 | 5.075 |
| 01:09 ET | 100 | 5.08 |
| 01:13 ET | 300 | 5.075 |
| 01:15 ET | 1323 | 5.085 |
| 01:18 ET | 500 | 5.09 |
| 01:20 ET | 1500 | 5.075 |
| 01:22 ET | 2100 | 5.075 |
| 01:24 ET | 100 | 5.075 |
| 01:26 ET | 7907 | 5.06 |
| 01:29 ET | 3000 | 5.0607 |
| 01:33 ET | 1163 | 5.08 |
| 01:36 ET | 29707 | 5.105 |
| 01:38 ET | 2252 | 5.09 |
| 01:40 ET | 5000 | 5.0999 |
| 01:42 ET | 300 | 5.0958 |
| 01:44 ET | 8078 | 5.105 |
| 01:45 ET | 1000 | 5.1 |
| 01:47 ET | 250 | 5.0901 |
| 01:49 ET | 100 | 5.095 |
| 01:51 ET | 855 | 5.085 |
| 01:54 ET | 500 | 5.09 |
| 01:58 ET | 7100 | 5.0899 |
| 02:00 ET | 500 | 5.095 |
Nov 12, 2024
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences, from 4:58PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:58PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
*DJ Vanda Pharmaceuticals 3Q Loss/Shr 9c >VNDA, from 4:02PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:02PM ET on Wednesday Nov 06, 2024 by Dow JonesVanda Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 4:02PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:02PM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 4, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA, from 4:46PM ET on Monday Nov 04, 2024 by Dow Jones
4:46PM ET on Monday Nov 04, 2024 by Dow Jones
Nov 2, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA, from 11:00AM ET on Saturday Nov 02, 2024 by Dow Jones
11:00AM ET on Saturday Nov 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vanda Pharmaceuticals Inc | 296.8M | -18.0x | -37.98% |
Akebia Therapeutics Inc | 410.2M | -8.8x | --- |
Sangamo Therapeutics Inc | 391.5M | -2.6x | --- |
Arcturus Therapeutics Holdings Inc | 458.0M | -7.6x | --- |
Sutro Biopharma Inc | 205.7M | -1.6x | --- |
Kamada Ltd | 337.5M | 18.7x | -22.48% |
Company Information
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Contact Information
- Headquarters
- SUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON, DC, United States 20037
- Phone
- 202-734-3400
- Fax
- 202-296-1450
Executives
- Chairman of the Board, President, Chief Executive Officer
- Mihael Polymeropoulos
- Chief Financial Officer, Senior Vice President, Treasurer
- Kevin Moran
- Senior Vice President, Chief Marketing Officer
- Joakim Wijkstrom
- Senior Vice President, General Counsel, Secretary
- Timothy Williams
- Senior Vice President - Business Development
- Gunther Birznieks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $296.8M |
|---|---|
Revenue (TTM) | $190.9M |
Shares Outstanding | 58.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.28 |
Book Value | $9.47 |
P/E Ratio | -18.0x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -19.64% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
